Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-145-2 | CAS number: 7789-17-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2011-05-24 to 2011-06-30
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and Guideline compliant study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- adopted 21st July 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- Regulation (EC) No 440/2008 of 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- hypoxanthine-guanine phosphoribosyl transferase enzyme locus (hprt) in cultured Chinese hamster cells
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: Ham's F12 medium
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix (phenobarbital (PB) and β-naphthoflavone (BNF) induced rat liver)
- Test concentrations with justification for top dose:
- Experiment 1, 5-hour treatment period without and with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL
Experiment 2, 20-hour treatment period without S9 mix:
625, 1250, 2500, 2750, 3000, 3250, 3500, 3750, and 4000 µg/mL
Experiment 2, 5-hour treatment period with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Ham's F12 medium (cell growth medium)
- Justification for choice of solvent/vehicle: good solubility in aqueous solutions - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: With S9 mix: 7,12-Dimethyl benzanthracene (DMBA); without S9 mix: Ethyl methanesulfonate (EMS)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration:
Experiment 1: 5 h (with and without S9 mix)
Experiment 2: 5 h (with S9 mix), 20 h (without S9 mix)
- Expression time (cells in growth medium): 24 h
- Selection time (if incubation with a selection agent): 8 days
SELECTION AGENT: 6-thioguanine (6 TG)
STAIN: Giemsa
NUMBER OF REPLICATIONS: 2
NUMBER OF EXPERIMENTS: 2
NUMBER OF CELLS EVALUATED: 1E6 cells: 5 plates at 2x1E5 cells/plate
DETERMINATION OF CYTOTOXICITY
- Method: cloning efficiency - Evaluation criteria:
- The test item would have been considered to be mutagenic in this assay if all the following criteria were met:
- The assay is valid.
- The mutant frequency at one or more doses is significantly greater than that of the relevant control.
- Increase of the mutant frequency is reproducible.
- There is a clear dose-response relationship.
The test item would have been considered to have shown no mutagenic activity if no increases were observed which met the criteria listed above. - Statistics:
- Statistical analysis was done with SPSS PC+ software for the following data:
mutant frequency between the negative (solvent) and the test item or positive control item treated groups. - Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: In pH no significant differences between treatment and control groups were observed.
- Effects of osmolality: In osmolality no significant differences between treatment and control groups were observed.
- Evaporation from medium: no evaporation expected
- Water solubility: A clear solution was obtained up to a concentration of 50 mg/mL.
- Precipitation: No precipitation in the medium was noted.
RANGE-FINDING/SCREENING STUDIES:
The dose selection cytotoxicity assay was performed as part of this study to establish an appropriate concentration range for the Main Mutation Assays (Experiments 1 and 2), both in the absence and in the presence of a metabolic activation system (rodent S9 mix). Toxicity was determined by comparing the colony forming ability of the treated groups to the negative (solvent) control and results were noted as percentage of cells in relation to the negative control. The results obtained were used for dose selection of the test item in the Main Mutation Assays.
COMPARISON WITH HISTORICAL CONTROL DATA:
The sensitivity of the tests and the efficacy of the S9 mix were demonstrated by large increases in mutation frequency in the positive control cultures. The mutation frequencies of the positive control cultures were consistent with the historical control data from the previous studies performed at this laboratory.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
In Experiment 1 in the absence and in the presence and in Experiment 2 in the presence of metabolic activation the upper examined test item dose level selected was 5000 µg cesium iodide /mL. In Experiment 2 in the absence of metabolic activation the upper examined test item dose level was 4000 µg cesium iodide /mL. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
The test item cesium iodide was not mutagenic in an in vitro mammalian cell gene mutation test performed with CHO-K1 (Chinese hamster ovary) cells. - Executive summary:
The test item, cesium iodide was tested in a HPRT Mammalian Gene Mutation Test in CHO-K1 cells according to OECD guideline 476 and EU method B.17.
The test item was dissolved in Ham's F12 medium and the following concentrations were selected on the basis of cytotoxicity investigations made in a preliminary study (without and with metabolic activation using S9 mix).
Two independent main experiments (both run in duplicate) were performed at the concentrations and treatment intervals given below:
Experiment 1, 5-hour treatment period without and with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL
Experiment 2, 20-hour treatment period without S9 mix:
625, 1250, 2500, 2750, 3000, 3250, 3500, 3750, 4000 µg/mL
Experiment 2, 5-hour treatment period with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL
In Experiment 1, there were no biologically or statistically significant increases in mutation frequency at any concentration tested, either in the absence or in the presence of metabolic activation. There were no statistical differences between treatment and control groups and no dose-response relationships were noted.
In Experiment 2, the mutant frequency of the cells did not show significant alterations compared to the concurrent control, when the test item was tested without S9 mix over a prolonged treatment period (20 hours). Furthermore, a five-hour treatment with in the presence of S9 mix did not cause significant increases in mutant frequency, further indicating that the findings in Experiment 1 were within the normal biological variation.
As in Experiment 1, in Experiment 2 no statistical differences between treatment and solvent control groups and no dose response relationships were noted. The sensitivity of the tests and the efficacy of the S9 mix were demonstrated by large increases in mutation frequency in the positive control cultures.
Cesium iodide tested both without and with metabolic activation (S9 mix), did not induce increases in mutant frequency in this test in Chinese hamster ovary cells. Cesium iodide was not mutagenic in this in vitro mammalian cell gene mutation test performed with CHO-K1 cells.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
In vitro and in vivo tests with cesium iodide and structural analogue substances showed that cesium iodide is neither considered mutagenic nor clastogenic:
Ames test
In compliance with the OECD Guideline No. 417 and EU Method B.13/14, five bacterial strains, Salmonella typhimurium TA 98, TA 100, TA 1535, TA 1537 and Escherichia coli WP2 uvrA were used to investigate the mutagenic potential of cesium iodide. Following concentrations were tested in two independent experiments composed of an initial mutation test (plate incorporation test) and a conformation mutation test (pre-incubation test): 5000, 1581, 500, 158, 50 and 15.8 μg test item/plate. Each assay was conducted with and without metabolic activation (S9 Mix). The concentrations, including the respective positive and negative controls, were tested in triplicate.
No substantial increases or decreases were observed in revertant colony numbers of any of the five test strains following treatment with cesium iodide at any concentration level, either in the presence or absence of metabolic activation (S9 Mix) in the performed experiments. Sporadic increases in revertant colony numbers compared to the vehicle control values and/or revertant colony numbers above the actual historical control data ranges were observed in both independently performed main experiments. However, there was no tendency of higher mutation rates with increasing concentrations beyond the generally acknowledged border of biological relevance in the performed experiments.
Thus, it can be concluded that the test item did not induce gene mutations by frameshift or base-pair substitution in the genome of the strains used. Therefore, the cesium iodide is considered non-mutagenic in this bacterial reverse mutation assay.
HPRT test
The test item, cesium iodide was tested in a Mammalian Gene Mutation Test in CHO-K1 cells. The test item was dissolved in Ham's F12 medium and the following concentrations were selected on the basis of cytotoxicity investigations made in a preliminary study (without and with metabolic activation using S9 mix).
Two independent main experiments (both run in duplicate) were performed at the concentrations and treatment intervals given below:
Experiment 1, 5-hour treatment period without and with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL
Experiment 2, 20-hour treatment period without S9 mix:
625, 1250, 2500, 2750, 3000, 3250, 3500, 3750, 4000 µg/mL
Experiment 2, 5-hour treatment period with S9 mix:
625, 1250, 2500, 3125, 3750, 4375, and 5000 µg/mL
In Experiment 1, there were no biologically or statistically significant increases in mutation frequency at any concentration tested, either in the absence or in the presence of metabolic activation. There were no statistical differences between treatment and control groups and no dose-response relationships were noted.
In Experiment 2, the mutant frequency of the cells did not show significant alterations compared to the concurrent control, when the test item was tested without S9 mix over a prolonged treatment period (20 hours). Furthermore, a five-hour treatment with in the presence of S9 mix did not cause significant increases in mutant frequency, further indicating that the findings in Experiment 1 were within the normal biological variation.
As in Experiment 1, in Experiment 2 no statistical differences between treatment and solvent control groups and no dose response relationships were noted. The sensitivity of the tests and the efficacy of the S9 mix were demonstrated by large increases in mutation frequency in the positive control cultures.
Cesium iodide tested both without and with metabolic activation (S9 mix), did not induce increases in mutant frequency in this test in Chinese hamster ovary cells. Cesium iodide was not mutagenic in this in vitro mammalian cell gene mutation test performed with CHO-K1 cells.
Chromosome aberration test (in vivo)
The test item cesium hydroxide monohydrate was used as read-across substance to determine the clastogenic potential of Cesium iodide in an in vivo Mammalian Bone Marrow Chromosome Aberration Test with in the Rat (Hsd.Brl.Han: Wistar rats) according to OECD guideline No. 475 and EU method B.11. The doses of the test item for the study was determined according to a preliminary oral toxicity study, the doses selected were 200, 400 and 800 mg /kg body weight. The measured concentrations of dosing solutions ranged from 95 % to 96 % of nominal concentrations at the analytical control. The measured concentrations of blood serum ranged from 25.2 to 112 mg Cs/L at the analytical control. Vehicle control and a positive control group were included. The test item and the positive control item Cyclophosphamide were dissolved in Aqua ad injectabilia. Treatment was carried out with the test item and the vehicle, once by the oral route with a constant treatment volume (10 mL/kg bw). Cyclophosphamide was administered once, intraperitoneally with a treatment volume of 1 mL/kg bw. In the vehicle, low, mid and high dose groups the sampling from bone marrow was performed twice, about at 18 and 42 hours after treatment. In animals treated with Cyclophosphamide (25 mg/kg bw), the sampling was performed only at 18 hours. Five animals per dose group were used on each occasion. 100 well spread metaphase cells were analysed for structural aberrations from each animal. 1000 nucleated cells were examined for measure of cytotoxicity from each animal. The frequencies of bone marrow cells showing structural chromosome aberrations for the vehicle, and positive control rats were within acceptable ranges and compatible with the historical control data for this laboratory. The positive control values showed a large, statistically significant increase over the negative control values, demonstrating the sensitivity of the test. The single oral administration of 200 mg/kg bw, 400 mg/kg bw and 800 mg/kg bw of the test item did not induce statistically or biologically significant increases in the number of bone marrow cells showing structural chromosome aberrations compared to concurrent controls. The frequency of the cells with structural chromosome aberrations did not show significant alterations compared to concurrent controls, with harvest at 18 or 42 hours following treatment start. Also, the single oral administration of 200 mg/kg bw, 400 mg/kg bw and 800 mg/kg bw of the test item not induce statistically significant decrease in the number of mitotic cells compared to concurrent controls. Under the described test conditions the tets item did not induce chromosome aberrations in the bone marrow of Hsd.Brl.Han: Wistar rats. Therefore, according to the results achieved in this in vivo mammalian bone marrow chromosome aberration test the test item cesium hydroxide monohydrate is not considered to be clastogenic and does therefore not confirm the clastogenic ptential observed in the in vitro chromosome aberration test with cesium hydroxide monohydrate (see below).
Based on these results cesium iodide is not considered to be clastogenic also.
Chromosome aberration test (in vitro)
The test item cesium hydroxide was used as read-across substance to determine the genotoxic potential of cesium iodide. The effect of cesium hydroxide on the chromosomal aberration was investigated using Chinese hamster lung fibroblasts (CHL cells), employing Mitomycin C (MMC) and Cyclophosphamide (CPA) as the positive controls for the tests without and with metabolic activation.
The inhibition test on cell growth and cell division was carried out to determine the dose levels of the test substance. From the result of this test, chromosomal aberration test was carried out using 375, 750 and 1500 µg/mL of the test substance for 24 hours treatment and 48 hours treatment by the direct method (without metabolic activation) and the metabolic activation method. MMC was employed at 0. 05 µg/mL for 24 hours treatment and 48 hours treatment by the direct method, and CPA at 10 µg/mL by the metabolic activation method.
The test substance induced no chromosomal aberration for 24 hours treatment by the direct method and by the metabolic activation method, however it showed structural chromosomal aberrations and numerical aberrations suspect positive effect at maximum dose of 1500 µg/mL in 48 hours treatment by the direct method.
Therefore, a re-examination test of chromosome aberration was carried out to confirm the structural chromosomal aberration and the numerical aberration suspect positive effect at the dose level of 750, 1125 and 1500 µg/mL for 48 hours treatment by the direct method. On the other hand, MMC and CPA induced evident chromosomal aberrations.
It is concluded that cesium hydroxide induced chromosomal aberration and numerical aberration by the direct method under the conditions tested. Therefore an in vivo chromosome aberration test was conducted in order to evaluate the clastogenic potential of cesium hydroxide.
Micronucleus test (in vivo)
Potential mutagenic activity of the structural analogous substance cesium chloride was examined in bone marrow of male and female NMRI BR mice. The frequencies of MPCEs for the untreated control mice were within an acceptable range and compatible with the historical control data for this labaratory. Cyclophosphamide treated mice (60 mg/kg bw) showed a large, statistically significant increase in the MPCEs number compared to the vehicle control, demonstrating an acceptable sensitivity of the test.
Slight, statistically significant (p<0.05) differences were observed in the number of MPCE in the male mice at 24 hours after the last treatment with 500 and 1000 mg/kg bw/day of cesiumchloride. However, the values observed in these groups were well below the mean historical control value of this laboratory, consequently they were considered to be of no biologically significance.
The intraperitoneal administration on two occasions, 24 hrs apart of 250 mg/kg bw/day, 500 mglkg bw/day and 1000 mg/kg body weight/day of cesium chloride did not induce any biologically relevant increase in the frequency of MPCEs in male or female mice at 24 after the last treatment compared to the vehicle control.
The percentage of PCE among total (polychromatic and normachromatic) erythrocytes in 1000 mg/kg bw/day dose groups of male was slightly lower than concurrent negative control value, but there was no clear evidence for test item induced hone marrow toxicity.
Under the conditions of this assay the test item cesium chloride did not induce any biologically relevant increase in the number of micronucleated polychromatic erythrocytes at dose Ievels of 250, 500 and 1000 mg/kg body weight after intraperitoneal administration on two occasions, 24 hrs apart in NMRI BR mice. Based on these results cesium iodide is also considered to be non-genotoxic.
Justification for selection of genetic toxicity endpoint
GLP and guideline compliant study with test item
Justification for classification or non-classification
Based on the results obtained in the in vitro and in vivo studies cesium iodide is not considered to be genotoxic/mutagenic or clastogenic and thus has not to be classified according to Regulation (EC) No 1272/2008. With respect to the read-across substance, the positive findings in the in vitro chromosome aberration test were not regarded to be biologically relevant considering the negative result of the in vivo chromosome aberration assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.